On June 6, 2025, Scotiabank upgraded Sarepta Therapeutics (LSE:0L35) from Sector Perform to Sector Outperform. The average one-year price target for the company is set at 94.26 GBX/share, representing a potential upside of 119.34% from the latest closing price of 42.97 GBX/share.
The projected annual revenue for Sarepta Therapeutics is 3,480 million GBP, reflecting a 55.82% growth, with an anticipated non-GAAP EPS of 13.02. Institutional ownership has decreased by 6.37% in the last quarter, with total shares owned dropping to 111,356K.
Key institutional holders include Capital International Investors with 9,061K shares (9.22% ownership) and Janus Henderson Group with 3,365K shares (3.42% ownership), both having reduced their portfolio allocations significantly over the last quarter.
